We are live on ! Find out more
GT

Glenmede Trust Portfolio holdings

AUM $20.4B
This Fund
S&P 500
This Quarter Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
Cap. Flow
-$417M
Cap. Flow %
-1.9%
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$89.3M
2
KEYS icon
Keysight
KEYS
+$86M
3
NKE icon
Nike
NKE
+$78.3M
4
APH icon
Amphenol
APH
+$76.5M
5
CMCSA icon
Comcast
CMCSA
+$72.3M

Top Sells

Rank Stock Value
1
CE icon
Celanese
CE
+$108M
2
MNST icon
Monster Beverage
MNST
+$97.8M
3
SBUX icon
Starbucks
SBUX
+$79.7M
4
TXN icon
Texas Instruments
TXN
+$67.3M
5
CNC icon
Centene
CNC
+$64.3M

Sector Composition

Rank Sector Weight
1 Technology 18.83%
2 Financials 13.42%
3 Healthcare 13.25%
4 Industrials 9.77%
5 Consumer Discretionary 7.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LM
2451
DELISTED
Legg Mason, Inc.
LM
$1K ﹤0.01%
34
-23
-40% -$854
CRCM
2452
DELISTED
CARE.COM, INC.
CRCM
$1K ﹤0.01%
83
+33
+66% +$396
DPLO
2453
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$1K ﹤0.01%
420
– –
UCFC
2454
DELISTED
United Community Financial Corp
UCFC
$1K ﹤0.01%
+149
New +$1.66K
MYRX
2455
DELISTED
MYREXIS INC COM STK
MYRX
$1K ﹤0.01%
100,980
– –
KPN
2456
DELISTED
ROYAL KPN NV ADS (EA REPTG 1 ORD SH)
KPN
$1K ﹤0.01%
+358
New +$1K
TI
2457
DELISTED
Telecom Italia
TI
$1K ﹤0.01%
187
– –
DOC
2458
DELISTED
PHYSICIANS REALTY TRUST
DOC
$1K ﹤0.01%
102
– –
AAOI icon
2459
Applied Optoelectronics
AAOI
$7.85B
$0 ﹤0.01%
54
– –
ACB
2460
Aurora Cannabis
ACB
$170M
$0 ﹤0.01%
5
-5
-50% -$1.86K
ACCO icon
2461
Acco Brands
ACCO
$381M
– –
-1,260
Closed -$12
ACRS icon
2462
Aclaris Therapeutics
ACRS
$750M
$0 ﹤0.01%
74
– –
ADAP
2463
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-375
Closed –
AGO icon
2464
Assured Guaranty
AGO
$3.78B
– –
-47
Closed -$2
AGYS icon
2465
Agilysys
AGYS
$2.91B
$0 ﹤0.01%
37
– –
AMG icon
2466
Affiliated Managers Group
AMG
$9.61B
– –
-250
Closed -$20
AMRX icon
2467
Amneal Pharmaceuticals
AMRX
$5.78B
$0 ﹤0.01%
114
– –
ANGI icon
2468
Angi Inc
ANGI
$240M
$0 ﹤0.01%
2
– –
APEI icon
2469
American Public Education
APEI
$907M
– –
-45
Closed -$1
ARKR icon
2470
Ark Restaurants
ARKR
$20.7M
– –
-15
Closed –
ARMK icon
2471
Aramark
ARMK
$15.2B
– –
-81,133
Closed -$2.55K
ATRC icon
2472
AtriCure
ATRC
$1.89B
$0 ﹤0.01%
29
– –
BBU
2473
DELISTED
Brookfield Business Partners
BBU
$0 ﹤0.01%
5
-88
-95% -$2.28K
BCDA icon
2474
BioCardia
BCDA
$12M
$0 ﹤0.01%
9
– –
BCO icon
2475
Brink's
BCO
$4.86B
$0 ﹤0.01%
9
– –
97 98
99
100 101

Similar funds

SLAM
Swiss Life Asset Management Zurich $20.4B AUM 28.71% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
P
&Partners Nashville, Tennessee $20.2B AUM 19.79% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Glenmede Trust's Q4 2019 Portfolio in Review

As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

  • Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
  • Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
  • Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
  • Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
  • Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
  • Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
  • Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.